13,500 Shares in Inspire Medical Systems, Inc. $INSP Acquired by ING Groep NV

ING Groep NV bought a new position in Inspire Medical Systems, Inc. (NYSE:INSP) in the third quarter, according to the company in its most recent disclosure with the SEC. The fund bought 13,500 shares of the company’s stock, valued at approximately $1,002,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Dragoneer Investment Group LLC boosted its stake in shares of Inspire Medical Systems by 81.4% in the 2nd quarter. Dragoneer Investment Group LLC now owns 2,354,411 shares of the company’s stock worth $305,532,000 after buying an additional 1,056,808 shares during the last quarter. Frontier Capital Management Co. LLC lifted its holdings in Inspire Medical Systems by 59.9% in the second quarter. Frontier Capital Management Co. LLC now owns 693,203 shares of the company’s stock valued at $89,957,000 after acquiring an additional 259,716 shares during the period. Man Group plc lifted its holdings in Inspire Medical Systems by 192.9% in the second quarter. Man Group plc now owns 380,298 shares of the company’s stock valued at $49,351,000 after acquiring an additional 250,456 shares during the period. Norges Bank purchased a new position in Inspire Medical Systems in the second quarter worth about $31,066,000. Finally, Braidwell LP grew its stake in shares of Inspire Medical Systems by 72.7% during the 2nd quarter. Braidwell LP now owns 522,410 shares of the company’s stock valued at $67,793,000 after purchasing an additional 220,000 shares during the period. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 2,000 shares of the company’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.48, for a total value of $254,960.00. Following the completion of the transaction, the director owned 26,046 shares of the company’s stock, valued at $3,320,344.08. This represents a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.10% of the stock is owned by insiders.

Inspire Medical Systems Price Performance

INSP opened at $59.78 on Friday. The company has a 50 day simple moving average of $92.88 and a two-hundred day simple moving average of $90.72. The firm has a market cap of $1.74 billion, a P/E ratio of 12.00, a PEG ratio of 6.35 and a beta of 0.74. Inspire Medical Systems, Inc. has a 1-year low of $53.11 and a 1-year high of $197.75.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Wednesday, February 11th. The company reported $1.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.96. The company had revenue of $269.08 million for the quarter, compared to analysts’ expectations of $264.02 million. Inspire Medical Systems had a net margin of 15.95% and a return on equity of 10.96%. Inspire Medical Systems’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.15 EPS. Equities analysts anticipate that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on INSP. Truist Financial lowered their price objective on shares of Inspire Medical Systems from $96.00 to $70.00 and set a “hold” rating on the stock in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Inspire Medical Systems in a report on Monday, December 29th. Evercore reiterated an “outperform” rating and set a $125.00 price target on shares of Inspire Medical Systems in a research note on Thursday, January 22nd. Jefferies Financial Group cut their price objective on shares of Inspire Medical Systems from $81.00 to $66.00 and set a “hold” rating for the company in a research report on Thursday. Finally, UBS Group set a $67.00 price objective on Inspire Medical Systems in a research note on Friday. Five equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $108.94.

Inspire Medical Systems News Roundup

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 beat: INSP reported $1.65 EPS vs. $0.69 expected and revenue of ~$269M, with expanded gross margins — a near-term operational positive. Zacks: INSP Beats Q4 Estimates
• Positive Sentiment: Some firms remain constructive at reduced targets — Mizuho and Piper Sandler kept outperform/overweight stances after lowering PTs, signaling there’s still perceived upside if reimbursement issues resolve. The Fly: Mizuho PT Cut
• Neutral Sentiment: Earnings call materials and transcript are available for detailed read-through (management commentary on coding, reimbursement and 2026 guide are key). Review to judge whether guidance risks are transitory. Seeking Alpha: Q4 Earnings Call Transcript
• Negative Sentiment: Management issued a 2026 revenue outlook of $950M–$1B and flagged a coding change plus reimbursement headwinds — the primary catalyst for the selloff risk and weaker forward expectations. MSN: 2026 Revenue Outlook & Coding Change
• Negative Sentiment: Multiple analyst downgrades and price-target cuts (Wells Fargo, Baird, Jefferies, Truist and others) followed the guidance and reimbursement concerns, increasing near-term selling pressure. Investing.com: Baird, Wells Fargo Cuts
• Negative Sentiment: The stock already experienced an earlier ~8% intraday decline after the coding/guidance news, showing how sensitive the market is to reimbursement updates. Investing.com: Shares Slide 8%

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.